Evogene Ltd. (NASDAQ:EVGN) Sees Significant Decline in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 23,600 shares, a decrease of 16.0% from the March 15th total of 28,100 shares. Based on an average trading volume of 24,400 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Stock Down 11.8 %

Shares of NASDAQ:EVGN opened at $1.12 on Wednesday. Evogene has a fifty-two week low of $0.95 and a fifty-two week high of $9.00. The company has a market cap of $6.01 million, a PE ratio of -0.25 and a beta of 1.37. The company’s 50-day moving average price is $1.30 and its 200 day moving average price is $1.63.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. During the same period in the previous year, the firm posted ($1.30) earnings per share.

Wall Street Analyst Weigh In

EVGN has been the subject of a number of research reports. Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th. StockNews.com started coverage on Evogene in a research report on Saturday. They set a “sell” rating for the company.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.